Why the study?
Does intravenous acebutolol (Sectral) alter haemodynamic parameters in patients with coronary artery disease or left ventricular asynergy?
Does intravenous acebutolol (Sectral) alter haemodynamic parameters in patients with coronary artery disease or left ventricular asynergy?
This early physiological study aimed to measure the acute haemodynamic effects of intravenous acebutolol in patients with coronary artery disease or left ventricular asynergy.
Early haemodynamic data on IV acebutolol in CAD remain hypothesis-generating; leaves open relevance to current practice.
The haemodynamic effects of a new beta-blocking agent, 'Sectral' (M & B I78o3A) were measured in 5 patients with coronary artery disease, 5 patients with regional left ventricular asynergy, and in 4 control subjects. The drug was given as a single intravenous dose of IO mg and then an additional 20 mg.
No takes yet. Share an insight, caveat, or question.
Lewis et al. (1973) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: